KEY FINDINGS
The global epigenomics market is forecasted to progress at 18.25% CAGR between the projected years of 2018-2026. Factors such as the high prevalence of cancer and other chronic diseases, better funding for research & development and increase in the demand for personalized medicine are driving this market’s growth.
MARKET INSIGHTS
The global epigenomics market is classified on the basis of technology, products, applications, area and segments.DNA methylation, histone methylation & acetylation and MicroRNA modification are the technologies deployed in this market.
Epigenomics product segment includes reagents, kits, instruments, enzymes and services.The market finds its application in oncology and non-oncology areas.
Diagnosis, drug discovery, therapy optimization and prognosis are the areas in which the global epigenomics market deals in. Market by segments is classified into epigenetic diagnostics, personalized medicines, epigenetic therapies and biomarkers.
REGIONAL INSIGHTS
Regional segmentation of the global epigenomics market is done into North America, Europe, Asia-Pacific and rest of the world.North America currently accounts for the highest revenue share in the epigenomics market.
The region is witnessing increasing collaborations between the big pharma companies to innovate and produce technologically advanced products.
COMPETITIVE INSIGHTS
Companies making progress in the epigenomics domain include Abbott Laboratories, Affymetrix, Agilent Technologies, Astellas Pharmaceuticals, Bayer Ag, Bio Vision, Celgene Corp, Epigenomics Ag, Epigentek, Glaxosmithkline, Illumina Inc, Johnson & Johnson, Laboratory Corp Of America Holdings, Merck Sharp & Dohme, Naturewise Biotech & Medicals Corp, Novartis Pharma Ag, Orchid Chemicals & Pharmaceuticals Limited, Tbg Diagnostics Limited, Rubicon Genomics, and Roche Holding Ag.